ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Patrick Amstuts, Chief Executive Officer, will participate in the 2023 RBC Capital Markets Global Healthcare Conference, in-person, May 16-17, 2023.
Details:
A copy of the presentation, as well as a recording of the fireside chat will be made available through the Molecular Partners website.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and infectious disease and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com ; Find us on Twitter - @MolecularPrtnrs.
For further details, please contact:
Seth Lewis, SVP IR and Strategy
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +1 781 420 2361
Antonio Ligi, Head of Communications
Zürich-Schlieren, Switzerland
This email address is being protected from spambots. You need JavaScript enabled to view it.
+41 44 755 57 53
Last Trade: | US$3.75 |
Daily Change: | -0.04 -0.95 |
Daily Volume: | 1,111 |
Market Cap: | US$123.100M |
January 07, 2024 January 05, 2024 December 14, 2023 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB